Format

Send to:

Choose Destination
See comment in PubMed Commons below
Br J Psychiatry. 2010 Oct;197(4):330-1. doi: 10.1192/bjp.bp.110.078105.

Nalmefene in the treatment of pathological gambling: multicentre, double-blind, placebo-controlled study.

Author information

  • 1Department of Psychiatry, University of Minnesota Medical School, 2450 Riverside Avenue, Minneapolis, MN 55454, USA. grant045@umn.edu

Erratum in

  • Br J Psychiatry. 2011 Jan;198:75.

Abstract

Pathological gambling is a disabling disorder experienced by about 1% of adults. We randomised 233 participants (41.6% women) 1:1:1 to nalmefene (20 or 40 mg) or placebo. In analyses performed using an intention-to-treat (ITT) population, nalmefene failed to show statistically significant differences from placebo on primary and secondary outcomes. Post hoc analyses of only participants who received a full titration of the medication for at least 1 week demonstrated that nalmefene 40 mg/day resulted in significantly greater reductions on the primary outcome measure. These findings suggest that medication dosing may be an important consideration in achieving symptom control.

PMID:
20884959
[PubMed - indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire
    Loading ...
    Write to the Help Desk